Document is current
Any future updates will be listed below
-
Authors
Assi, Reem
Quintiens, Jolien
Monteagudo, Silvia
Lories, Rik J. https://orcid.org/0000-0002-5986-3092
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (1SF4522N, 11A7320N, 18B2122N, G097118N, G0B2120N, G099922N, G056822N, G059223N)
Onderzoeksraad, KU Leuven (C14/20/117)
- License Information
-
More Information
Article History
Accepted: 20 March 2023
First Online: 17 April 2023
Declarations
:
: Leuven Research and Development, the technology transfer office of KU Leuven, has received consultancy and speaker fees on behalf of R.J.L. from Abbvie, Amgen (Celgene), Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Biosplice Therapeutics (formerly Samumed), Viatris and UCB. The other authors declare that they have no competing financial interests.
: R.A. and J.Q. are the recipients of PhD fellowships (1SF4522N and 11A7320N, respectively) and R.L. is the recipient of a senior clinical investigator fellowship (18B2122N) from the Flanders Research Foundation (FWO-Vlaanderen). Research on osteoarthritis in the Laboratory of Tissue Homeostasis and Disease is supported by grants from FWO-Vlaanderen (G097118N, G0B2120N, G099922N, G056822N and G059223N) and from KU Leuven (C14/20/117).
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: R.A and J.Q contributed equally as first authors and were responsible for the literature review and first draft of the manuscript. S.M. and R.L contributed to the further development of the manuscript.
